PURPOSE: Nanovesicles composed of the phospholipid dioleylphosphatidylserine (DOPS) and a fusogenic protein, saposin C (SapC), selectively target and induce apoptotic cell death in a variety of human cancer cells in vitro and in vivo. We tested whether such tumor-homing nanovesicles are capable of delivering fluorescent probes and magnetic resonance (MR) contrast agents to cancerous tissue to aid in earlier detection and improve visualization. PROCEDURES: SapC-DOPS nanovesicles labeled with either a far-red fluorescent probe (CellVue® Maroon, CVM) or conjugated with a dextran coated MR contrast agent, ultrasmall superparamagnetic iron oxide (USPIO), were systemically administrated into xenografts for tumor detection using optical and MR imaging systems. RESULTS: SapC-DOPS nanovesicles were effectively detected in vivo in tumor-bearing animals using both optical and MR imaging techniques, thereby demonstrating the cancer-selective properties of these nanovesicles. CONCLUSIONS: SapC-DOPS nanovesicles offer promise as a new and robust theranostic agent for broad cancer-selective detection, visualization, and potential therapy.
PURPOSE: Nanovesicles composed of the phospholipiddioleylphosphatidylserine (DOPS) and a fusogenic protein, saposin C (SapC), selectively target and induce apoptotic cell death in a variety of humancancer cells in vitro and in vivo. We tested whether such tumor-homing nanovesicles are capable of delivering fluorescent probes and magnetic resonance (MR) contrast agents to cancerous tissue to aid in earlier detection and improve visualization. PROCEDURES: SapC-DOPS nanovesicles labeled with either a far-red fluorescent probe (CellVue® Maroon, CVM) or conjugated with a dextran coated MR contrast agent, ultrasmall superparamagnetic iron oxide (USPIO), were systemically administrated into xenografts for tumor detection using optical and MR imaging systems. RESULTS:SapC-DOPS nanovesicles were effectively detected in vivo in tumor-bearing animals using both optical and MR imaging techniques, thereby demonstrating the cancer-selective properties of these nanovesicles. CONCLUSIONS:SapC-DOPS nanovesicles offer promise as a new and robust theranostic agent for broad cancer-selective detection, visualization, and potential therapy.
Authors: Erik M Shapiro; Stanko Skrtic; Kathryn Sharer; Jonathan M Hill; Cynthia E Dunbar; Alan P Koretsky Journal: Proc Natl Acad Sci U S A Date: 2004-07-15 Impact factor: 11.205
Authors: Willem J M Mulder; Gustav J Strijkers; Geralda A F van Tilborg; Arjan W Griffioen; Klaas Nicolay Journal: NMR Biomed Date: 2006-02 Impact factor: 4.044
Authors: J W Bulte; Y Hoekstra; R L Kamman; R L Magin; A G Webb; R W Briggs; K G Go; C E Hulstaert; S Miltenyi; T H The Journal: Magn Reson Med Date: 1992-05 Impact factor: 4.668
Authors: Xiaoyang Qi; Zhengtao Chu; Yonatan Y Mahller; Keith F Stringer; David P Witte; Timothy P Cripe Journal: Clin Cancer Res Date: 2009-09-08 Impact factor: 12.531
Authors: Patrick M Winter; John Pearce; Zhengtao Chu; Christopher M McPherson; Ray Takigiku; Jing-Huei Lee; Xiaoyang Qi Journal: J Magn Reson Imaging Date: 2014-05-06 Impact factor: 4.813
Authors: Jeffrey Wojton; Zhengtao Chu; Haritha Mathsyaraja; Walter H Meisen; Nicholas Denton; Chang-Hyuk Kwon; Lionel Ml Chow; Mary Palascak; Robert Franco; Tristan Bourdeau; Sherry Thornton; Michael C Ostrowski; Balveen Kaur; Xiaoyang Qi Journal: Mol Ther Date: 2013-06-04 Impact factor: 11.454
Authors: Mahaboob K Sulaiman; Zhengtao Chu; Victor M Blanco; Subrahmanya D Vallabhapurapu; Robert S Franco; Xiaoyang Qi Journal: Mol Cancer Date: 2015-04-08 Impact factor: 27.401
Authors: Zhengtao Chu; Shadi Abu-Baker; Mary B Palascak; Syed A Ahmad; Robert S Franco; Xiaoyang Qi Journal: PLoS One Date: 2013-10-04 Impact factor: 3.240